MedTrace Logo

A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants

NCT05288816 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-02-05

Study results available
· View outcomes & findings →

Summary

This study evaluated the safety and tolerability of single and multiple doses (400 and 800 milligrams \[mg\]) of ALXN1210 following intravenous administration to healthy Japanese participants.

Conditions

  • Healthy

Interventions

DRUG

ALXN1210

Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-18
Primary Completion
2017-07-05
Completion
2017-07-05
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05288816 on ClinicalTrials.gov